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Standard chemotherapy for advanced epithelial ovarian cancer is a combination of platinum-paclitaxel. One strategy to
improve the outcome for patients is to add other agents to standard therapy. Doxil is active in relapsed disease and has a
response rate of 25% in platinum-resistant relapsed disease. A dose ﬁnding study of doxil-carboplatin-paclitaxel was therefore
undertaken in women receiving ﬁrst-line therapy. Thirty-one women with epithelial ovarian cancer or mixed Mullerian tumours
of the ovary were enrolled. The doses of carboplatin, paclitaxel and doxil were as follows: carboplatin AUC 5 and 6; paclitaxel,
135 and 175 mg m
72; doxil 20, 30, 40 and 50 mg m
72. Schedules examined included treatment cycles of 21 and 28 days,
and an alternating schedule of carboplatin-paclitaxel (q 21) with doxil being administered every other course (q 42). The
dose-limiting toxicities were found to be neutropenia, stomatitis and palmar plantar syndrome and the maximum tolerated
dose was deﬁned as; carboplatin AUC 5, paclitaxel 175 mg m
72 and doxil 30 mg m
72 q 21. Reducing the paclitaxel dose to
135 mg m
72 did not allow the doxil dose to be increased. Delivering doxil on alternate cycles at doses of 40 and
50 mg m
72 also resulted in dose-limiting toxicities. The recommended doses for phase II/III trials are carboplatin AUC 6,
paclitaxel 175 mg m
72, doxil 30 mg m
72 q 28 or carboplatin AUC 5, paclitaxel 175 mg m
72, doxil 20 mg m
72 q 21. Grade
3/4 haematologic toxicity was common at the recommended phase II doses but was short lived and not clinically important
and non-haematologic toxicities were generally mild and consisted of nausea, paraesthesiae, stomatitis and palmar plantar
syndrome.
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Epithelial ovarian cancer (EOC) is the ﬁfth commonest cancer in
women and despite the use of platinum-based chemotherapy, the
prognosis for women with advanced disease remains poor with a
5-year disease-speciﬁc survival of 28% (Cancer Research Campaign,
1991). The standard ﬁrst-line chemotherapy for advanced disease is
a platinum-paclitaxel combination. McGuire et al (1996) demon-
strated that treatment of epithelial ovarian cancer with cisplatin-
paclitaxel resulted in improved overall survival compared to treat-
ment with cisplatin-cyclophosphamide. This result was conﬁrmed
by the Intergroup study (Piccart et al, 2000) and subsequent trials
have demonstrated the improved toxicity proﬁle and equal efﬁcacy
of carboplatin-paclitaxel compared with cisplatin-paclitaxel (du
Bois et al, 1999; Neijt and du Bois, 1999; Ozols et al, 1999).
It is thought that the poor outcome of ovarian cancer is due to
the outgrowth of platinum and paclitaxel resistant clones. Over the
last decade, a number of agents have been identiﬁed that have
activity in platinum and paclitaxel refractory ovarian cancer. The
addition of these agents to ﬁrst-line platinum-paclitaxel regimens,
either in combination or sequentially, has been proposed as means
of improving results of chemotherapy in this disease.
Doxorubicin has single-agent activity in relapsed ovarian cancer
(Hubbard et al, 1978) and two meta-analyses of trials using plati-
num-based therapy (The Ovarian Cancer Meta-Analysis Project,
1991; A’Hern and Gore, 1995) suggest that the addition of anthra-
cyclines increases overall survival. ICON2, a randomised trial
comparing single-agent carboplatin with cisplatin-doxorubicin-
cyclophosphamide (CAP) did not conﬁrm this suggestion and
CAP resulted in greater toxicity without an improvement in
outcome (The Icon Collaborators, 1998). There are two trials
comparing carboplatin-paclitaxel with carboplatin-paclitaxel-epiru-
bicin as ﬁrst-line treatment of epithelial ovarian cancer but one is
still accruing (EORTC) and the other is not fully reported yet
(AGO). Phase I/II trials of doxorubicin combined with carbopla-
tin-paclitaxel on a 3 weekly schedule with G-CSF support or
doxorubicin-carboplatin with weekly paclitaxel (Hill et al, 1997)
show that both regimens are active but have signiﬁcant toxicity
and are only suitable for ﬁt patients.
The liposomal formulation of doxorubicin known as Doxil (or
Caelyx) is a formulation of standard doxorubicin encapsulated in
pegylated liposomes. Its toxicity proﬁle is different from that of
standard doxorubicin and in single-agent trials, the dose-limiting
toxicities are stomatitis, myelosuppression and palmar-plantar
syndrome (PPS), similar to that seen with prolonged infusional
ﬂuorouracil. PPS is said to occur at dose rates of greater than
10 mg m
72 per week. Cardiac toxicity is not apparent with cumu-
lative doses exceeding 500 mg m
72 (Safra et al, 2000).
Doxil has been shown to have single agent activity against
relapsed ovarian cancer in a number of trials (Muggia et al,
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women with platinum and paclitaxel-resistant epithelial ovarian
cancer, a response rate of 25% and a progression-free survival of
5.7 months was observed, at dose of 50 mg m
72 given 4 weekly
(Muggia et al, 1997). The non-overlapping toxicity proﬁles and
evidence of some degree of non-cross resistance makes the combi-
nation of doxil with carboplatin-paclitaxel an attractive prospect.
We therefore undertook a dose-ﬁnding study of the combina-
tion of doxil, carboplatin and paclitaxel.
PATIENTS AND METHODS
Inclusion and exclusion criteria
Patients with a diagnosis of epithelial ovarian cancer, fallopian tube
carcinoma, mixed Mu ¨llerian tumour or primary peritoneal carci-
noma requiring ﬁrst-line chemotherapy (FIGO stage IC to IV)
were eligible for entry into the study. Patients were required to
have an ECOG performance status of 0–1, creatinine clearance
460 ml min
71, left ventricular ejection fraction 550%, bilirubin
and transaminases 5twice upper limit normal and adequate
haematological function, deﬁned by haemoglobin 410 g dl
71,
neutrophil count 43610
9 l
71 and platelets 4100610
9 l
71.
Women with a prior history of malignancy were included provided
they had a disease-free interval of at least 3 years. Patients with a
history of cardiac disease, symptomatic peripheral neuropathy or
tumours of borderline histology were not eligible. The trial proto-
col was approved by the Research Ethics Committee of the Royal
Marsden Hospital and all patients were required to give fully
informed written consent.
Treatment
Patients received doxil, followed by carboplatin then paclitaxel.
Paclitaxel 135 mg m
72 or 175 mg m
72 was administered in 5%
dextrose, as a 3 h infusion. The dose of carboplatin was calculated
according to the Calvert formula (Calvert et al, 1989) to achieve an
area under the concentration-time curve (AUC) of 5–6 mg ml
71
min
71. The glomerular ﬁltration rate was estimated by
51Cr EDTA
clearance.
Carboplatin was given as an i.v. infusion over 1 h and liposomal
doxorubicin was administered as a 1-h infusion in 250 ml of 5%
dextrose. All patients received the following premedication: dexa-
methasone 20 mg p.o. 12 and 6 h prior to chemotherapy,
chlorpheniramine 10 mg i.v. and cimetidine 300 mg i.v. 30 min
prior to chemotherapy and ondansetron 8 mg i.v. with chemother-
apy. In addition, patients received dexamethasone 4 mg t.d.s. and
metoclopramide 20 mg tds for 4 days after treatment.
The dose escalation schedule is shown in Table 1. The ﬁrst
patient at each dose level was evaluated for toxicity over one full
cycle before subsequent patients were entered at that level. Three
patients were entered at each dose level and an interval of at least
4 weeks was required between the last patient entering a dose level
and the next dose level commencing.
Dose-limiting toxicity/maximum tolerated dose
Toxicities were graded according to the Common Toxicity Criteria,
(CTC) version 2.0. Non haematological dose limiting toxicity
(DLT) was deﬁned as an episode of CTC grade 3 or 4 toxicity
requiring dose modiﬁcation. In the case of haematological toxicity,
DLT was deﬁned as an absolute neutrophil count of
51.0610
9 l
71 lasting for more than 7 days or associated with
sepsis or an absolute platelet count of 550610
9 l
71 for more than
7 days or requiring platelet transfusion. Anaemia requiring transfu-
sion was not classiﬁed as DLT. Any DLT occurring in two patients
in a cohort resulted in the cohort being expanded from 3–6
patients. Dose escalation did not continue until no further episodes
of DLT were observed in the expanded cohort.
The maximum tolerated dose was deﬁned as the dose level at
which DLT occurred in more than two thirds of patients enrolled
in that level.
Toxicity and response assessment
Blood was taken weekly for full blood count, differential, urea,
creatinine, electrolytes and liver function tests. Treatment toxicity
was assessed prior to each cycle. Left ventricular ejection fraction
was measured by gated-pool radionuclide scan prior to cycle one
and on completion of treatment. Audiometry was performed on
entry into the trial and then as clinically indicated.
Tumour response was assessed by clinical examination,
computed axial tomography (CT) and serum CA125 level. Clinical
examination and CA125 were performed before each cycle and 4
weeks after the last cycle. CT scanning was performed prior to
study entry, after every two courses and 4–6 weeks after the last
treatment.
At each assessment, patients with progressive disease stopped
treatment and those with stable disease or evidence of response
received further cycles. The standard number of cycles was consid-
ered to be six; however treatment was continued for up to eight
cycles if there was ongoing disease response. Interval cytoreductive
surgery was permitted if clinically indicated.
Dose modiﬁcation
Patients who experienced haematological DLT received no further
doxil. It was expected that the main DLT would be mucosal toxi-
city rather than myelosuppression. Thus, it was not planned that
G-CSF should be routinely incorporated into the regimen. Those
who developed any grade of palmar-plantar syndrome (PPS) were
given pyridoxine 50 mg thrice daily. Grade 3 or 4 stomatitis or PPS
resulted in a treatment delay of 1 week and then treatment contin-
ued with a 25% reduction in doxil dose, provided sufﬁcient healing
had occurred. Patients who had persistent grade 3 or 4 toxicity
after 1 week off chemotherapy received no further doxil.
Mild-to-moderate doxil-related anaphylactoid reactions were
managed by reducing the infusion rate and giving additional anti-
histamines and steroids as appropriate. Patients who had severe or
life-threatening reactions received no further doxil. Anapylactoid
reactions to doxil are not considered to be dose-related, so their
occurrence was not classiﬁed as DLT. Patients who experienced
such a reaction were taken off trial and replaced at that dose-level.
Antitumour activity
Tumour response was assessed using standard WHO criteria.
Complete response (CR) required normalisation of serum CA125
in addition to disappearance of all known disease. All responses
had to be conﬁrmed by two observations not less than 4 weeks
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Table 1 Dose escalation scheme
Carboplatin Paclitaxel Doxil Cycle
AUC mg m
72 mg m
72 days
Level I 6 175 20 28
Level II 6 175 30 28
Level III 5 175 20 21
Level IV 5 175 30 21
Level V 5 135 30 21
Level VI 5 175 40 21 and 42*
Level VII 5 175 50 21 and 42*
*Doxil given on alternative cycles.
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Rustin and colleagues (Bridgewater et al, 1999).
RESULTS
Patient characteristics
Thirty-one patients were entered into the trial and their character-
istics are summarised in Table 2. Three patients had anaphylactoid
reactions to the ﬁrst dose of doxil. Thus 28 patients were evaluated
for toxicity. Twenty-six patients had epithelial ovarian cancer and
two patients had mixed Mullerian tumours of the ovary. The
median age of the patients was 54 years and most had advanced
disease; two patients had stage Ic and two had stage II disease,
and one patient had relapsed ovarian cancer having originally
had no chemotherapy for a stage I tumour.
Toxicity
Nonhaematological toxicity at each level dose level is shown in
Table 3. At dose levels I, II and III grade 3/4 toxicity (exclud-
ing alopecia) occurred in four patients. Two patients had
stomatitis (one each at level I and II), one patient had vomit-
ing (level III) and one patient had short-lived grade 3 PPS
(level II).
Increasing the doxil dose to 30 mg m
72 (level IV) resulted in
grade 3/4 stomatitis (one patient), PPS (two patients) and infec-
tion (three patients, two episodes of neutropenic sepsis, one
non-neutropenic). Two patients were enrolled at level V before
it became apparent that DLT occurred at level IV. Both patients
treated at level V suffered grade 3/4 side effects (stomatitis,
PPS) and it was felt inappropriate to continue recruitment at
this level. In view of the unacceptable toxicity resulting from
3-weekly liposomal doxorubicin, a protocol amendment, study-
ing the effect of increasing the liposomal doxorubicin dose
interval to 6 weeks (levels VI and VII) was submitted to and
approved by both the institutional protocol review board and
the institutional research ethics committee. At level VI, three
patients had grade 3 stomatitis. One patient at this level devel-
oped grade 3 fatigue and declined further doxil. At level VII,
one patient experienced grade 3 stomatitis and the other devel-
oped grade 3 stomatitis and grade 4 neurological toxicity (acute
cerebellar ataxia) after cycle one. No cause was identiﬁed
despite extensive investigation and she received no further doxil
or paclitaxel.
No patients developed congestive cardiac failure or evidence of
impaired left ventricular function on gated-pool scan. The mean
change in ejection fraction for the 21 patients in whom two scans
were available was 72% (range +13% to 716%).
CTC grade 3/4 haematologic toxicity for each dose level is
shown in Table 4. The majority of nadirs were short-lived. Haema-
tologic DLT occurred in one patient out of the 12 treated at dose
levels I–III (thrombocytopenia; grade 3, level III). Grade 3 throm-
bocytopenia occurred in an additional patient at this level, one
cycle after the doxil was stopped due to stomatitis. At dose level
IV there were two episodes of neutropenic sepsis with the neutro-
penia lasting 11 days in both cases. No haematological DLT was
recorded in the two patients treated at dose level V. At level VI,
one patient had neutropenic sepsis and two had prolonged neutro-
penia requiring cessation of liposomal doxorubicin. At level VII,
only three courses which included the intended dose of doxil were
given.
Dose modiﬁcations
Table 5 shows the DLTs, dose modiﬁcations and delays in treat-
ment. The mean treatment delay per cycle was 0.5 days (level I,
II), 0.3 days (level III), 2.3 days (level IV, V), 4 days (level VI).
A dose reduction was made in one patient at dose level I (25%
reduction in doxil) after cycle two because of grade 3 stomatitis.
At level II, one patient had doxil stopped without treatment delay
after four cycles for grade 3 stomatitis. At level III one patient had
doxil stopped after ﬁve cycles for grade 4 thrombocytopenia requir-
ing platelet transfusion. An additional patient in this level had an
incorrect 25% dose reduction in doxil after cycle two for grade 2
stomatitis but received no further treatment due to disease progres-
sion. All patients treated at dose levels IV and V required dose
modiﬁcation during treatment. Five of six patients at level VI
and both patients in level VII required dose modiﬁcation.
Two patients died at dose level III, in both cases the deaths were
not thought to be treatment-related. The ﬁrst patient had been
anticoagulated for a recently diagnosed proximal deep vein throm-
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Table 2 Patient characteristics
Age Median (range) 54 (27–68)
Stage Ic 2
II 2
III 17
IV 6
Relapsed Ic 1
Residual disease Not recorded 9
52c m 9
2–5cm 4
45c m 6
Histology Serous 15
Endometroid 6
Adenocarcinoma 2
Mixed Mullerian tumour 2
Clear cell 3
Tumour grade Not recorded 7
10
26
31 5
Table 4 Grade 3/4 haematologic toxicity
Dose level I II III IV V VI VII
Neutrophils 11/20 14/16 12/32 21/24 3/11 9/21 2/3
Platelets 0/20 2/16 1/32 1/24 0/11 1/21 0/3
Haemoglobin 0/20 0/16 1/32 2/24 0/11 0/21 0/3
Number of cycles in which grade 3 or 4 toxicity was observed/Total number of cycles
at each dose level.
Table 3 Grade III/IV nonhaematological toxicity – worst grade per
patient
I II III IV V VI VII
Level (n=3) (n=3) (n=6) (n=6) (n=2) (n=6) (n=2)
Alopecia 3/3 3/3 5/6 5/6 2/2 5/6 1/2
Nausea 0/3 0/3 0/6 0/6 0/2 1/6 1/2
Vomiting 0/3 0/3 1/6 0/6 0/2 0/6 0/2
Diarrhoea 0/3 0/3 0/6 0/6 0/2 1/6 1/2
Stomatitis 1/3 1/3 0/6 1/6 1/2 3/6 1/2
PPS 0/3 1/3* 0/6 2/6 1/2 0/6 0/2
Constipation 0/3 0/3 0/6 0/6 0/2 0/6 0/2
Motor 0/3 0/3 0/6 0/6 0/2 0/6 0/2
Sensory 0/3 0/3 0/6 0/6 0/2 0/6 0/2
Hearing 0/3 0/3 0/6 0/6 0/2 0/6 0/2
*Healed after 1 week delay, no dose reduction.
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of pulmonary embolism was made. The second patient died 15
days after cycle six and although a clinical diagnosis of pneumonia
was made by the general practitioner, on further investigation the
mode of death was more consistent with pulmonary embolism.
Maximum tolerated dose
The maximum tolerated doses were deﬁned as level IV (carboplatin
AUC 5, paclitaxel 175 mg m
72, doxil 30 mg m
72 q 21), level V
(carboplatin AUC 5, paclitaxel 135 mg m
72, doxil 30 mg m
72 q
21) and level VI (carboplatin AUC 5, paclitaxel 175 mg m
72 q
21, doxil 40 mg m
72 q 42). Two possible phase II doses have been
deﬁned, level II (carboplatin AUC 6, paclitaxel 175 mg m
72, lipo-
somal doxorubicin 30 mg m
72 q 28) and level III (carboplatin
AUC 5, paclitaxel 175 mg m
72, doxil 20 mg m
72 q 21). At level
III there was only one episode of grade 3 toxicity, thrombocytope-
nia resulting in a dose delay of 3 days. Three more patients were
treated at this dose level without further DLT.
Tumour response
Response data was collected regardless of dose level and number of
courses completed which included doxil. Antitumour effects were
apparent in 67% of patients with radiologically measurable or
evaluable disease. The CA125 response rate was 87%.
DISCUSSION
Doxil has been tested in a number of cancers, some considered
responsive to anthracyclines, others thought to be refractory. In
addition to the trials in ovarian cancer, single agent liposomal
doxorubicin has been tested in breast cancer, (Ranson et al,
1997) soft tissue sarcoma (Judson et al, 2001) head and neck
cancer (Harrington et al, 2001) melanoma (Ellerhorst et al, 1999)
renal cell carcinoma (Law et al, 1994) and pancreatic carcinoma
(Schwartz and Casper, 1995) Doxil has been studied in combina-
tion with other agents including docetaxel, (Malik et al, 1998;
Drinkard et al, 1999; Hirsch et al, 1999) paclitaxel, (Israel et al,
1998; Langley et al, 1998; Moore et al, 1998; Woll et al, 1999)
cisplatin, (Klein et al, 1999) vinorelbine (Burstein et al, 1999;
Gebbia et al, 1999; Jahanzeb et al, 1999) and gemcitabine (Rivera
et al, 2001). There have been no trials of doxil-carboplatin
published. Four trials of doxil-paclitaxel have deﬁned a MTD for
doxil of 30 mg m
72 every 3 weeks with doses of paclitaxel ranging
from 150–200 mg m
72. In these studies, dose-limiting toxicities
include stomatitis, PPS and myelosuppression. Three dose-ﬁnding
studies of the related taxane, docetaxel showed similar dose-limit-
ing toxicity.
The current study has deﬁned the maximum tolerated dose of
doxil in combination with carboplatin-paclitaxel as 30 mg m
72
when given on a 3-weekly schedule. Increasing the dose interval
of doxil to 6 weeks did not allow the dose administered to be
increased. A dose of 40 mg m
72 administered 6 weekly resulted
in dose-limiting toxicity in four of six patients. Similar dose-limit-
ing toxicity was observed in a trial of doxil 60 mg m
72 q 6 weekly
and paclitaxel 175 mg m
72 q 3 weekly (Langley et al, 1998).
The current study was not designed to assess efﬁcacy but the
response rates are comparable with other ﬁrst-line regimens.
However, it should be noted that our recommended phase II/III
dose for doxil in combination with carboplatin-paclitaxel is less
than the dose used in phase II studies of single agent doxil in
relapsed disease. Future strategies include the sequential adminis-
tration of doxil with platinum-paclitaxel, either as a single agent
or in combination with either carboplatin or paclitaxel, and trials
of so-called sequential couplets are already underway.
In conclusion, this is the ﬁrst study to deﬁne schedules for a
triple combination of carboplatin-paclitaxel-doxil that can be taken
forward into future phase II or III studies. The dose schedules are
as follows; carboplatin AUC 6, paclitaxel 175 mg m
72, doxil
30 mg m
72 q 28 and carboplatin AUC 5, paclitaxel 175 mg m
72,
doxil 20 mg m
72 q 21. At these doses, the combination is well
tolerated and feasible to administer.
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Table 5 Dose limiting toxicities, dose modiﬁcation and treatment delays
No of CTC No of Treatment
patients Toxicity grade course Dose modiﬁcation delay (days)
Level I 1 Stomatitis 3 2 25% reduction 7
Level II 1 Stomatitis 3 5 D stopped 0
1 PPS 3 5 None 7
Level III 1 Platelets 4 6 D stopped 3
I Stomatitis 2 3 25% reduction 0
Level IV 2 Neutropenic sepsis 3 3, 6 D stopped 7, 20
2 PPS 3 5, 6 D stopped 0, 7
1 Stomatitis 3 6 D stopped 7
1 Sepsis 4 2 D stopped 8
Level V 1 Stomatitis 3 5 D stopped 7
1 PPS 3 6 D stopped 7
Level VI 2 Stomatitis 3 3 D stopped, D reduced 10, 3
1 Fatigue 3 1 D stopped 0
1 Neutropenic sepsis 3 3 D stopped 6
1 Neutropenia 3 3 D stopped 10
Level VII 1 Stomatitis 3 3 D stopped 2
1 Stomatitis, cerebellar ataxia 4 1 D, paclitaxel stopped 0
D=doxil.
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